Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...

Gilead’s Tomas Cihlar and his team of researchers have spent decades studying HIV—and their latest innovation could be a game changer for prevention.

Prism Health North Texas was one of 32 sites to enroll patients in the global clinical trial for Idvynso. The U.S. Food and Drug Administration approved the treatment for people living with HIV ...

Two quick injections in the lower belly will give Mr Belmos Gom, a 29-year-old resident of Lira City, more than 99 percent protection against HIV infection for six months. Mr Gom is one of the first ...

A little-known tree from Brazil’s Atlantic Forest may hold a surprising weapon against COVID-19. Researchers discovered that ...

Executive Orders and Policy Updates - In the end of 2025 and the first quarter of 2026, the Trump administration and federal ...

A DISGRACED former Met Police chief has admitted to a secret double life of drug-fuelled “chem sex” sessions with men off ...

Six years ago, Dr. Michael Peluso and his team launched a first-of-its-kind long COVID tissue bank. They’ve been working to understand the disease ever since.

Good afternoon, everyone, and welcome to Gilead's First Quarter 2026 Earnings Conference Call. My name is Rebecca, and I'll be today's host. [Operator Instructions] Now I'll hand the call over to ...

NOTE: This article is carved from a speech delivered by the author on the occasion of A Freshers Welcome program organized by the Agriculture Science Department of Fumbisi Senior High School in ...